{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T19:14:19Z","timestamp":1777662859195,"version":"3.51.4"},"reference-count":88,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.ucl.2019.09.005","type":"journal-article","created":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T12:40:47Z","timestamp":1574167247000},"page":"23-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Predictors of Response to Intravesical Therapy"],"prefix":"10.1016","volume":"47","author":[{"given":"Roger","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ucl.2019.09.005_bib1","first-page":"180","article-title":"Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J\u00a0Urol"},{"issue":"1","key":"10.1016\/j.ucl.2019.09.005_bib2","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance Bacillus Calmette-Guerin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.ucl.2019.09.005_bib3","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.eururo.2007.10.006","article-title":"Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: multivariate analysis of data from four randomized CUETO trials","volume":"53","author":"Fernandez-Gomez","year":"2008","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.ucl.2019.09.005_bib4","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.eururo.2011.05.045","article-title":"Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review","volume":"60","author":"van den Bosch","year":"2011","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.ucl.2019.09.005_bib5","first-page":"2195","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model","volume":"182","author":"Fernandez-Gomez","year":"2009","journal-title":"J\u00a0Urol"},{"issue":"6","key":"10.1016\/j.ucl.2019.09.005_bib6","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1200\/JCO.2014.57.6967","article-title":"Improving selection criteria for early cystectomy in high-grade t1 bladder cancer: a meta-analysis of 15,215 patients","volume":"33","author":"Martin-Doyle","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2019.09.005_bib7","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ucl.2005.01.001","article-title":"Radical cystectomy for bladder cancer: the case for early intervention","volume":"32","author":"Chang","year":"2005","journal-title":"Urol Clin North Am"},{"issue":"2 Pt 1","key":"10.1016\/j.ucl.2019.09.005_bib8","first-page":"494","article-title":"Superficial bladder carcinoma treated with bacillus Calmette-Guerin: progression-free and disease specific survival with minimum 10-year followup","volume":"167","author":"Davis","year":"2002","journal-title":"J\u00a0Urol"},{"issue":"1","key":"10.1016\/j.ucl.2019.09.005_bib9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1023\/A:1014444601158","article-title":"Multivariate evaluation of factors affecting recurrence, progression, and survival in patients with superficial bladder cancer treated with intravesical bacillus Calmette-Guerin (Tokyo 172 strain) therapy: significance of concomitant carcinoma in situ","volume":"33","author":"Takashi","year":"2002","journal-title":"Int Urol Nephrol"},{"issue":"2","key":"10.1016\/j.ucl.2019.09.005_bib10","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0090-4295(99)00116-8","article-title":"Intravesical bacille Calmette-Guerin in Stage T1 grade 3 bladder cancer therapy: a 7-year follow-up","volume":"54","author":"Hurle","year":"1999","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.ucl.2019.09.005_bib11","first-page":"797","article-title":"Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy","volume":"148","author":"Cookson","year":"1992","journal-title":"J\u00a0Urol"},{"issue":"1","key":"10.1016\/j.ucl.2019.09.005_bib12","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.urology.2007.03.024","article-title":"Age and outcome of superficial bladder cancer treated with bacille Calmette-Guerin therapy","volume":"70","author":"Herr","year":"2007","journal-title":"Urology"},{"issue":"5","key":"10.1016\/j.ucl.2019.09.005_bib13","first-page":"1602","article-title":"Low dose Pasteur bacillus Calmette-Guerin regimen in stage T1, grade 3 bladder cancer therapy","volume":"156","author":"Hurle","year":"1996","journal-title":"J\u00a0Urol"},{"issue":"2","key":"10.1016\/j.ucl.2019.09.005_bib14","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0090-4295(01)01603-X","article-title":"Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guerin: 18-year experience","volume":"59","author":"Pansadoro","year":"2002","journal-title":"Urology"},{"issue":"5","key":"10.1016\/j.ucl.2019.09.005_bib15","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.eururo.2017.10.003","article-title":"Predicting response to intravesical bacillus Calmette-guerin immunotherapy: are we there yet? a systematic review","volume":"73","author":"Kamat","year":"2018","journal-title":"Eur Urol"},{"issue":"10","key":"10.1016\/j.ucl.2019.09.005_bib16","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1200\/JCO.1996.14.10.2646","article-title":"Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guerin therapy: correlation to clinical outcome","volume":"14","author":"Lacombe","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.ucl.2019.09.005_bib17","first-page":"1079","article-title":"p53 status does not predict initial clinical response to bacillus Calmette-Guerin intravesical therapy in T1 bladder tumors","volume":"159","author":"Pages","year":"1998","journal-title":"J\u00a0Urol"},{"issue":"5","key":"10.1016\/j.ucl.2019.09.005_bib18","first-page":"1655","article-title":"Long-term efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ: relationship of progression to histological response and p53 nuclear accumulation","volume":"157","author":"Ovesen","year":"1997","journal-title":"J\u00a0Urol"},{"issue":"6","key":"10.1016\/j.ucl.2019.09.005_bib19","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1159\/000020364","article-title":"p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists?","volume":"38","author":"Schmitz-Drager","year":"2000","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.ucl.2019.09.005_bib20","first-page":"1768","article-title":"A\u00a0comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma","volume":"164","author":"Halling","year":"2000","journal-title":"J\u00a0Urol"},{"issue":"3","key":"10.1016\/j.ucl.2019.09.005_bib21","first-page":"862","article-title":"Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guerin therapy for bladder cancer: results of a prospective trial","volume":"187","author":"Kamat","year":"2012","journal-title":"J\u00a0Urol"},{"issue":"5","key":"10.1016\/j.ucl.2019.09.005_bib22","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/bju.13186","article-title":"Novel fluorescence in situ hybridization-based definition of bacille Calmette-Guerin (BCG) failure for use in enhancing recruitment into clinical trials of intravesical therapies","volume":"117","author":"Kamat","year":"2016","journal-title":"BJU Int"},{"issue":"12","key":"10.1016\/j.ucl.2019.09.005_bib23","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1038\/ng.3692","article-title":"Clonal evolution of chemotherapy-resistant urothelial carcinoma","volume":"48","author":"Faltas","year":"2016","journal-title":"Nat Genet"},{"issue":"10","key":"10.1016\/j.ucl.2019.09.005_bib24","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/2159-8290.CD-14-0623","article-title":"Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma","volume":"4","author":"Van Allen","year":"2014","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.ucl.2019.09.005_bib25","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","article-title":"Impact of molecular Subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy","volume":"72","author":"Seiler","year":"2017","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ucl.2019.09.005_bib26","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/1078-0432.CCR-04-1101","article-title":"Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer","volume":"11","author":"Gu","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"46","key":"10.1016\/j.ucl.2019.09.005_bib27","doi-asserted-by":"crossref","first-page":"75176","DOI":"10.18632\/oncotarget.12661","article-title":"Genomic characterization of high-risk non-muscle invasive bladder cancer","volume":"7","author":"Meeks","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.ucl.2019.09.005_bib28","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ccell.2016.05.004","article-title":"Comprehensive transcriptional analysis of early-stage urothelial carcinoma","volume":"30","author":"Hedegaard","year":"2016","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.ucl.2019.09.005_bib29","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2017.05.032","article-title":"Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets","volume":"72","author":"Pietzak","year":"2017","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2019.09.005_bib30","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.eururo.2011.10.029","article-title":"Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guerin","volume":"62","author":"Palou","year":"2012","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2019.09.005_bib31","first-page":"364","article-title":"Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer","volume":"167","author":"Saint","year":"2002","journal-title":"J\u00a0Urol"},{"issue":"3","key":"10.1016\/j.ucl.2019.09.005_bib32","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.eururo.2015.08.029","article-title":"Finasteride reduces risk of bladder cancer in a large prospective screening study","volume":"69","author":"Morales","year":"2016","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.ucl.2019.09.005_bib33","first-page":"1634","article-title":"The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy","volume":"175","author":"Joudi","year":"2006","journal-title":"J\u00a0Urol"},{"issue":"4","key":"10.1016\/j.ucl.2019.09.005_bib34","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.eururo.2014.05.033","article-title":"The effect of age on the efficacy of maintenance bacillus Calmette-Guerin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911","volume":"66","author":"Oddens","year":"2014","journal-title":"Eur Urol"},{"issue":"24","key":"10.1016\/j.ucl.2019.09.005_bib35","doi-asserted-by":"crossref","first-page":"5746","DOI":"10.1200\/JCO.2005.01.598","article-title":"Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival","volume":"23","author":"Leibovici","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.ucl.2019.09.005_bib36","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/bju.12844","article-title":"The role of functional polymorphisms in immune response genes as biomarkers of bacille Calmette-Guerin (BCG) immunotherapy outcome in bladder cancer: establishment of a predictive profile in a Southern Europe population","volume":"116","author":"Lima","year":"2015","journal-title":"BJU Int"},{"issue":"5","key":"10.1016\/j.ucl.2019.09.005_bib37","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrmicro.2016.17","article-title":"The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism","volume":"14","author":"Spanogiannopoulos","year":"2016","journal-title":"Nat Rev Microbiol"},{"issue":"6356","key":"10.1016\/j.ucl.2019.09.005_bib38","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1126\/science.aah5043","article-title":"Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine","volume":"357","author":"Geller","year":"2017","journal-title":"Science"},{"issue":"6264","key":"10.1016\/j.ucl.2019.09.005_bib39","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1126\/science.aac4255","article-title":"Commensal Bifidobacterium promotes antitumor immunity and facilitates anti\u2013PD-L1 efficacy","volume":"350","author":"Sivan","year":"2015","journal-title":"Science"},{"issue":"6264","key":"10.1016\/j.ucl.2019.09.005_bib40","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.aad1329","article-title":"Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota","volume":"350","author":"V\u00e9tizou","year":"2015","journal-title":"Science"},{"issue":"6371","key":"10.1016\/j.ucl.2019.09.005_bib41","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1\u2013based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.ucl.2019.09.005_bib42","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/sj.bjc.6602026","article-title":"Role of urothelial cells in BCG immunotherapy for superficial bladder cancer","volume":"91","author":"Bevers","year":"2004","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.ucl.2019.09.005_bib43","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1177\/1933719112466306","article-title":"Adhesion of Lactobacillus iners AB-1 to human fibronectin: a key mediator for persistence in the vagina?","volume":"20","author":"McMillan","year":"2013","journal-title":"Reprod Sci"},{"issue":"5","key":"10.1016\/j.ucl.2019.09.005_bib44","first-page":"1702","article-title":"The predictive value of purified protein derivative results on complications and prognosis in patients with bladder cancer treated with bacillus Calmette-Guerin","volume":"169","author":"Bilen","year":"2003","journal-title":"J\u00a0Urol"},{"issue":"2","key":"10.1016\/j.ucl.2019.09.005_bib45","first-page":"483","article-title":"Intravesical versus intravesical plus intradermal bacillus Calmette-Guerin: a prospective randomized study in patients with recurrent superficial bladder tumors","volume":"155","author":"Luftenegger","year":"1996","journal-title":"J\u00a0Urol"},{"issue":"137","key":"10.1016\/j.ucl.2019.09.005_bib46","doi-asserted-by":"crossref","first-page":"137ra72","DOI":"10.1126\/scitranslmed.3003586","article-title":"Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer","volume":"4","author":"Biot","year":"2012","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.ucl.2019.09.005_bib47","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.euf.2018.08.015","article-title":"Background and update for S1602 \"a phase III randomized trial to evaluate the influence of BCG strain differences and T cell priming with intradermal BCG before intravesical therapy for BCG-naive high-grade non-muscle-invasive bladder cancer","volume":"4","author":"Svatek","year":"2018","journal-title":"Eur Urol Focus"},{"issue":"4","key":"10.1016\/j.ucl.2019.09.005_bib48","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0302-2838(03)00371-3","article-title":"The side effects of Bacillus Calmette-Guerin in the treatment of Ta T1 bladder cancer do not predict its efficacy: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial","volume":"44","author":"Sylvester","year":"2003","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ucl.2019.09.005_bib49","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0090-4295(01)00921-9","article-title":"Leukocyturia as a predictor of tolerance and efficacy of intravesical BCG maintenance therapy for superficial bladder cancer","volume":"57","author":"Saint","year":"2001","journal-title":"Urology"},{"issue":"10","key":"10.1016\/j.ucl.2019.09.005_bib50","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1158\/0008-5472.CAN-04-0374","article-title":"Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guerin-induced antitumor activity","volume":"64","author":"Ludwig","year":"2004","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.ucl.2019.09.005_bib51","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.eururo.2006.06.006","article-title":"HSP90 expression: a new predictive factor for BCG response in stage Ta-T1 grade 3 bladder tumours","volume":"51","author":"Lebret","year":"2007","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ucl.2019.09.005_bib52","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.urology.2009.02.053","article-title":"Efficacy of bacille Calmette-Guerin immunotherapy predicted by expression of antigen-presenting molecules and chemokines","volume":"74","author":"Videira","year":"2009","journal-title":"Urology"},{"issue":"15","key":"10.1016\/j.ucl.2019.09.005_bib53","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.1158\/1078-0432.CCR-06-0595","article-title":"Effect of human leukocyte antigen class I expression of tumor cells on outcome of intravesical instillation of bacillus calmette-guerin immunotherapy for bladder cancer","volume":"12","author":"Kitamura","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ucl.2019.09.005_bib54","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/jcp.47.4.309","article-title":"Induction of ICAM 1 expression on bladder tumours by BCG immunotherapy","volume":"47","author":"Jackson","year":"1994","journal-title":"J\u00a0Clin Pathol"},{"issue":"6","key":"10.1016\/j.ucl.2019.09.005_bib55","first-page":"1636","article-title":"Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall","volume":"147","author":"Prescott","year":"1992","journal-title":"J\u00a0Urol"},{"issue":"6","key":"10.1016\/j.ucl.2019.09.005_bib56","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/j.1442-2042.2006.01697.x","article-title":"Bacillus Calmette-Guerin-pulsed dendritic cells stimulate natural killer T cells and gammadeltaT cells","volume":"14","author":"Naoe","year":"2007","journal-title":"Int J Urol"},{"issue":"9","key":"10.1016\/j.ucl.2019.09.005_bib57","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1111\/j.1464-410X.2004.05176.x","article-title":"Urine dendritic cells: a noninvasive probe for immune activity in bladder cancer?","volume":"94","author":"Beatty","year":"2004","journal-title":"BJU Int"},{"issue":"6","key":"10.1016\/j.ucl.2019.09.005_bib58","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.eururo.2009.01.040","article-title":"Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guerin immunotherapy","volume":"55","author":"Ayari","year":"2009","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ucl.2019.09.005_bib59","first-page":"1894","article-title":"Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation","volume":"181","author":"Takayama","year":"2009","journal-title":"J\u00a0Urol"},{"issue":"7","key":"10.1016\/j.ucl.2019.09.005_bib60","first-page":"1762","article-title":"Intravesical Bacillus Calmette-Guerin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guerin","volume":"47","author":"Ratliff","year":"1987","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.ucl.2019.09.005_bib61","first-page":"53","article-title":"Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall","volume":"144","author":"Bohle","year":"1990","journal-title":"J\u00a0Urol"},{"issue":"26","key":"10.1016\/j.ucl.2019.09.005_bib62","doi-asserted-by":"crossref","first-page":"39916","DOI":"10.18632\/oncotarget.9537","article-title":"Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical bacillus calmette-guerin therapy in bladder cancer","volume":"7","author":"Pichler","year":"2016","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.ucl.2019.09.005_bib63","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/1097-0215(20010601)92:5<697::AID-IJC1245>3.0.CO;2-Z","article-title":"NK cells are essential for effective BCG immunotherapy","volume":"92","author":"Brandau","year":"2001","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/j.ucl.2019.09.005_bib64","first-page":"2660","article-title":"The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study","volume":"178","author":"Yutkin","year":"2007","journal-title":"J\u00a0Urol"},{"issue":"1","key":"10.1016\/j.ucl.2019.09.005_bib65","doi-asserted-by":"crossref","first-page":"45.e23-30","DOI":"10.1016\/j.urolonc.2013.06.008","article-title":"Predicting response to bacillus Calmette-Guerin (BCG) in patients with carcinoma in situ of the bladder","volume":"32","author":"Nunez-Nateras","year":"2014","journal-title":"Urol Oncol"},{"issue":"4","key":"10.1016\/j.ucl.2019.09.005_bib66","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00262-016-1945-z","article-title":"Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer","volume":"66","author":"Pichler","year":"2017","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"10.1016\/j.ucl.2019.09.005_bib67","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/ijc.11352","article-title":"Urinary IL-2 assay for monitoring intravesical bacillus Calmette-Guerin response of superficial bladder cancer during induction course and maintenance therapy","volume":"107","author":"Saint","year":"2003","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.ucl.2019.09.005_bib68","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0302-2838(03)00048-4","article-title":"Do prognostic parameters of remission versus relapse after Bacillus Calmette-Guerin (BCG) immunotherapy exist?. analysis of a quarter century of literature","volume":"43","author":"Saint","year":"2003","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.ucl.2019.09.005_bib69","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1046\/j.1365-2249.2003.02071.x","article-title":"Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guerin (BCG) mediated antitumour activity","volume":"131","author":"Nadler","year":"2003","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"10.1016\/j.ucl.2019.09.005_bib70","first-page":"1906","article-title":"Interleukin-6\/10 ratio as a prognostic marker of recurrence in patients with intermediate risk urothelial bladder carcinoma","volume":"178","author":"Cai","year":"2007","journal-title":"J\u00a0Urol"},{"issue":"3","key":"10.1016\/j.ucl.2019.09.005_bib71","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3892\/etm.2012.634","article-title":"Prediction of response to bacillus Calmette-Guerin treatment in non-muscle invasive bladder cancer patients through interleukin-6 and interleukin-10 ratio","volume":"4","author":"Cai","year":"2012","journal-title":"Exp Ther Med"},{"issue":"6","key":"10.1016\/j.ucl.2019.09.005_bib72","first-page":"2129","article-title":"Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin","volume":"164","author":"Thalmann","year":"2000","journal-title":"J\u00a0Urol"},{"issue":"2","key":"10.1016\/j.ucl.2019.09.005_bib73","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1442-2042.2007.01696.x","article-title":"Intravesical instillation therapy with bacillus Calmette-Guerin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guerin immunotherapy","volume":"14","author":"Shintani","year":"2007","journal-title":"Int J Urol"},{"issue":"2","key":"10.1016\/j.ucl.2019.09.005_bib74","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.eururo.2015.06.023","article-title":"Cytokine panel for response to intravesical therapy (CyPRIT): nomogram of changes in urinary cytokine levels predicts patient response to bacillus Calmette-Guerin","volume":"69","author":"Kamat","year":"2016","journal-title":"Eur Urol"},{"issue":"10","key":"10.1016\/j.ucl.2019.09.005_bib75","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41585-018-0055-4","article-title":"Mechanisms of BCG immunotherapy and its outlook for bladder cancer","volume":"15","author":"Pettenati","year":"2018","journal-title":"Nat Rev Urol"},{"issue":"1","key":"10.1016\/j.ucl.2019.09.005_bib76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.ucl.2019.09.005_bib77","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.it.2012.10.004","article-title":"Type I interferon response and innate immune sensing of cancer","volume":"34","author":"Fuertes","year":"2013","journal-title":"Trends Immunol"},{"issue":"5","key":"10.1016\/j.ucl.2019.09.005_bib78","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","article-title":"STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors","volume":"41","author":"Woo","year":"2014","journal-title":"Immunity"},{"issue":"7213","key":"10.1016\/j.ucl.2019.09.005_bib79","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nature07317","article-title":"STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling","volume":"455","author":"Ishikawa","year":"2008","journal-title":"Nature"},{"issue":"6121","key":"10.1016\/j.ucl.2019.09.005_bib80","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1126\/science.1232458","article-title":"Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway","volume":"339","author":"Sun","year":"2013","journal-title":"Science"},{"issue":"47","key":"10.1016\/j.ucl.2019.09.005_bib81","doi-asserted-by":"crossref","first-page":"19386","DOI":"10.1073\/pnas.1215006109","article-title":"STING manifests self DNA-dependent inflammatory disease","volume":"109","author":"Ahn","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.ucl.2019.09.005_bib82","doi-asserted-by":"crossref","first-page":"P228","DOI":"10.1186\/2051-1426-2-S3-P228","article-title":"STING contributes to anti-glioma immunity via triggering type-I IFN signals in the tumor microenvironment","volume":"2","author":"Ohkuri","year":"2014","journal-title":"J\u00a0Immunother Cancer"},{"issue":"10","key":"10.1016\/j.ucl.2019.09.005_bib83","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.4049\/jimmunol.1402051","article-title":"Cutting edge: STING mediates protection against colorectal tumorigenesis by governing the magnitude of intestinal inflammation","volume":"193","author":"Zhu","year":"2014","journal-title":"J\u00a0Immunol"},{"issue":"30","key":"10.1016\/j.ucl.2019.09.005_bib84","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1200\/JCO.2017.72.3064","article-title":"Intravesical rAd-IFNalpha\/Syn3 for patients with high-grade, bacillus Calmette-Guerin-refractory or relapsed non-muscle-invasive bladder cancer: a phase II randomized study","volume":"35","author":"Shore","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.ucl.2019.09.005_bib85","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1158\/0008-5472.CAN-08-2281","article-title":"Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment","volume":"69","author":"Harlin","year":"2009","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.ucl.2019.09.005_bib86","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/cncr.22588","article-title":"PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression","volume":"109","author":"Inman","year":"2007","journal-title":"Cancer"},{"issue":"10064","key":"10.1016\/j.ucl.2019.09.005_bib87","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"issue":"200","key":"10.1016\/j.ucl.2019.09.005_bib88","doi-asserted-by":"crossref","first-page":"200ra116","DOI":"10.1126\/scitranslmed.3006504","article-title":"Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells","volume":"5","author":"Spranger","year":"2013","journal-title":"Sci Transl Med"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014319300837?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014319300837?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:38:38Z","timestamp":1758807518000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014319300837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":88,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0094014319300837"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2019.09.005","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of Response to Intravesical Therapy","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2019.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}